Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compart
about
The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implicationsCardiovascular Complications of HIV-Associated Immune DysfunctionExtensive HIV-1 intra-host recombination is common in tissues with abnormal histopathologyIs There Sufficient Evidence for a Causal Association between Antiretroviral Therapy and Diabetes in HIV-infected Patients? A Meta-analysis.Ageing and inflammation in patients with HIV infection.Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future DirectionsPresence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.The metabolic syndromeDyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi MetropolisStudy of Body Composition and Metabolic Parameters in HIV-1 Male Patients.Associations between physical activity and sedentary time on components of metabolic syndrome among adults with HIVImpact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients.Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.Prevalence of metabolic syndrome in human immunodeficiency virus - infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria.Taming HIV-related inflammation with physical activity: a matter of timingIncreased coronary artery calcium score and noncalcified plaque among HIV-infected men: relationship to metabolic syndrome and cardiac risk parameters.Anatomical localization of commensal bacteria in immune cell homeostasis and diseaseImpaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.Understanding diabetes in patients with HIV/AIDSDiabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in South IndiaBody mass index and the risk of incident noncommunicable diseases after starting antiretroviral therapyPrevalence of cardiometabolic risk factors in Hispanics living with HIV.Metabolic abnormalities and coronary heart disease risk in human immunodeficiency virus-infected adults.Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey.Controversies in HIV-associated neurocognitive disordersCombination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular diseaseA cross-sectional assessment of metabolic syndrome in HIV-infected people of low socio-economic status receiving antiretroviral therapyHypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.HIV therapy, metabolic syndrome, and cardiovascular risk.Epidemiology and management of antiretroviral-associated cardiovascular disease.South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.Diabetes mellitus and risk factors in human immunodeficiency virus-infected individuals at Jimma University Specialized Hospital, Southwest EthiopiaThe effect of aging, nutrition, and exercise during HIV infection.Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome.Influences of gender in metabolic syndrome and its components among people living with HIV virus using antiretroviral treatment in Hawassa, southern Ethiopia.A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population.Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation.HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact.Serum adiponectin in HIV-1 and hepatitis C virus mono- and co-infected Kenyan injection drug users.
P2860
Q24598812-41DE4A70-2DA5-4FC4-B95A-3F3401D43FA4Q28084981-B9D7CC45-E235-4A6C-A608-A5141315116BQ28475143-AB030293-1A19-4E32-AC94-9EC788EB8FE0Q30234685-96E3AD71-7B74-4FD1-80C2-75E61EE2F917Q30244296-25DB66AF-83E8-4A79-A4E6-76575C1DED91Q30244921-387CA412-1F42-4279-A145-E8FB06BCA74CQ33389734-D6D16D64-53DD-4B85-8E18-DA911F6319C2Q33569142-5F0A0B42-C7FF-4B60-A675-AC7C3460150DQ33751516-7ACA41FE-F69A-42A3-AB83-B1ECD62D574AQ33804247-A5A7BEC4-095E-4C38-B635-F14CEF091E5EQ34005771-9CD50345-B697-4970-BF4B-4A0B06F5A24AQ34024617-ADDFB2AA-A254-488D-A9D1-AE2712C5C68CQ34125560-2F2DE8D9-F580-48B8-9BA0-88AB45270F7BQ34136175-9E7F2862-120B-4ACB-A5D1-BDB39C75039CQ34266259-708C2A02-A32A-472E-9477-463B0FB9DDA4Q34283290-298748EF-BD63-4568-AB5C-D964573B3E86Q34425509-0AF6E88D-0F85-4544-BCD3-3F20430CA5ADQ34512603-1256B86A-B938-4518-B3DC-71B8EE126289Q34515251-F87A5A22-E04E-40F2-9296-7EE583EF7BB7Q34622631-5DCB2E54-3763-4CF3-8B32-78457031723BQ34718097-8B871E8E-8D58-4D0C-9A3C-D804E95C1A05Q34766026-89628E7F-E3A0-43B4-BFBC-DCB0ED20CE1AQ34896246-45A9B36A-BDBC-4D4C-A705-87B191AFEEECQ34942750-DA0EE637-9359-43B4-9D82-00A2A93B550CQ35037015-1452187D-892B-4988-B87E-778D53743A2EQ35101789-01B3DEC0-E3E1-4BCE-9FE7-6CB24FFD97C6Q35104006-218A3D3C-19BB-4E8B-81E6-D9B496A0D76EQ35166766-94794B64-F7BF-4018-89B8-6D50B4C7F257Q35176441-32E42414-6A21-442E-9FC9-081F73A0328EQ35194399-0061BF64-B031-4B31-B9F7-59D70B780B9FQ35338096-4EEBAADC-5A29-4D23-B4B2-5D2CD63AFB4CQ35352433-7B17E294-5A1F-4DF9-8898-EE7E7E5291E9Q35492280-551915D7-711D-4EF6-94D1-F2B7F00E5BB2Q35557264-667EFACA-2BD9-4239-85ED-63FA0F4AFD6CQ35617409-CE0CD908-B3EB-4DDC-BC62-2523C6CB41DAQ35946656-C587A0D5-385D-4F29-A5CC-3FEBE746F10FQ35967926-AA84D913-32F6-4055-90FA-66C693495F55Q36001196-A06F4EE5-8B88-4949-927C-498F569C02B7Q36007239-CE412C0C-A8FE-4A50-9AFB-972CA328A12BQ36051167-58025AB3-1DF6-4A12-BABB-DA4793921AF7
P2860
Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compart
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Prevalence of metabolic syndro ...... ce, disturbed body fat compart
@en
Prevalence of metabolic syndro ...... ce, disturbed body fat compart
@nl
type
label
Prevalence of metabolic syndro ...... ce, disturbed body fat compart
@en
Prevalence of metabolic syndro ...... ce, disturbed body fat compart
@nl
prefLabel
Prevalence of metabolic syndro ...... ce, disturbed body fat compart
@en
Prevalence of metabolic syndro ...... ce, disturbed body fat compart
@nl
P2093
P356
P1433
P1476
Prevalence of metabolic syndro ...... ce, disturbed body fat compart
@en
P2093
Andrew Carr
David Cooper
Handan Wand
Katherine Samaras
Sean Emery
P304
P356
10.2337/DC06-1075
P407
P50
P577
2007-01-01T00:00:00Z